Zevra Denmark A/S
CVR: 43259326
Previous names: KemPharm Denmark A/S
Zevra Denmark A/S is currently facing significant financial challenges, as evidenced by its negative profit margins and declining equity. In 2024, the company reported a revenue of 70,973,000 DKK but incurred a substantial loss of 132,114,000 DKK, indicating a troubling trajectory compared to a loss of 20,506,000 DKK in 2023 and 7,406,000 DKK in 2022. The equity position has deteriorated sharply, falling to -159,627,000 DKK in 2024, which raises concerns about its financial stability and ability to attract investment. As a player in the research and experimental development sector, Zevra's current financial state suggests it may struggle to maintain its position without significant operational or strategic changes.
AI-generated summary
Overview
- Company type
- A/S
- Aktieselskab
- Founded
- 13.5.2022
Details
- Capital
- 400.000 kr.
Contact
Advertising protectedPurpose
Selskabets formål er forskning, udvikling, produktion, markedsføring, salg og/eller licensudstedelse af medicinske produkter til behandling af forskellige sygdomme samt hermed beslægtede aktiviteter efter bestyrelsens skøn.
Location
Financials
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 71 mio. | -132.1 mio. | 178.2 mio. | -159.6 mio. | 4 | |
History
Ownership
Management
Directors
Board
Founders
Production units (1)
Similar companies
Companies in the same industry and area